F S&P 500
5,068.75 -38.75 (-0.76%) F Dow Jones
38,582.00 -98.00 (-0.25%) F Nasdaq
17,419.75 -244.75 (-1.39%) E-mini Russell 2000 Index Futur
2,009.00 +2.20 (+0.11%) Petróleo
82.94 +0.13 (+0.16%) Oro
2,330.90 -7.50 (-0.32%)
Novavax, Inc. (NVAX)
Fuera de horario:
Novavax, Inc.
700 Quince Orchard Road
Gaithersburg, MD 20878
United States
240 268 2000
https://www.novavax.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 1,543
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. John Joseph Trizzino B.S., M.B.A. | President & COO | 641.22k | N/D | 1960 |
| Mr. James Patrick Kelly C.F.A. | Executive VP, CFO & Treasurer | 644.32k | N/D | 1966 |
| Mr. Stanley Charles Erck | Advisor | 1.09M | N/D | 1948 |
| Mr. John Charles Jacobs M.B.A. | CEO & Director | N/D | N/D | 1967 |
| Mr. Richard P. Crowley | Executive VP & COO | N/D | N/D | 1957 |
| Mr. Troy Morgan Esq., J.D. | Senior VP & Chief Compliance Officer | N/D | N/D | 1971 |
| Mr. Mark Casey | Executive VP, Chief Legal Officer & Corporate Secretary | N/D | N/D | N/D |
| Ms. Erika S. Trahan | Associate Director of Investor & Public Relations | N/D | N/D | N/D |
| Mr. Ian J. Watkins | Executive VP & Chief Human Resources Officer | N/D | N/D | 1963 |
| Ms. Silvia Taylor M.B.A. | Executive VP and Chief Corporate Affairs & Advocacy Officer | N/D | N/D | N/D |
Descripción
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Gestión corporativa
La calificación ISS Governance QuickScore de Novavax, Inc. a partir del 1 de abril de 2024 es 4. Las puntuaciones principales son Auditoría: 6; Junta: 4; Derechos del accionista: 5; Compensación: 5.
